Compare · ABEO vs TSHA
ABEO vs TSHA
Side-by-side comparison of Abeona Therapeutics Inc. (ABEO) and Taysha Gene Therapies Inc. (TSHA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both companies sit in the Health Care sector. ABEO focuses on Biotechnology: Pharmaceutical Preparations, while TSHA focuses on Biotechnology: Biological Products (No Diagnostic Substances).
- TSHA is the larger of the two at $1.22B, about 4.6x ABEO ($265.9M).
- ABEO has been more active in the news (5 items in the past 4 weeks vs 2 for TSHA).
- TSHA has more recent analyst coverage (18 ratings vs 8 for ABEO).
- Company
- Abeona Therapeutics Inc.
- Taysha Gene Therapies Inc.
- Price
- -
- -
- Market cap
- $265.9M
- $1.22B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2020
- News (4w)
- 5
- 2
- Recent ratings
- 8
- 18
Abeona Therapeutics Inc.
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead programs include EB-101, an autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa; ABO-102, an adeno-associated virus-based gene therapy for Sanfilippo syndrome type A; and ABO-101, an AAV-based gene therapy for Sanfilippo syndrome type B. The company also develops ABO-201 to treat CLN3 disease; ABO-401 for the treatment of cystic fibrosis; and ABO-5OX for the treatment of genetic eye disorders. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was founded in 1974 and is headquartered in New York, New York.
Taysha Gene Therapies Inc.
Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-101 for the treatment of GM2 gangliosidosis; TSHA-118 for the treatment of CLN1 disease; and TSHA-102 for the treatment of Rett syndrome. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy treatments; and collaboration with Yale University to advance mini-gene payloads for an AAV gene therapy for the treatment of neurodevelopmental disorders. The company was incorporated in 2019 and is based in Dallas, Texas.
Latest ABEO
- Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Chief Executive Officer Seshadri Vishwas sold $101,091 worth of shares (19,608 units at $5.16), decreasing direct ownership by 2% to 1,286,500 units (SEC Form 4) to satisfy tax liability
- Chief Financial Officer Vazzano Joseph Walter sold $47,385 worth of shares (9,191 units at $5.16), decreasing direct ownership by 2% to 482,888 units (SEC Form 4) (withholding obligation)
- SVP, Chief Legal Officer O'Malley Brendan M. sold $34,682 worth of shares (6,727 units at $5.16), decreasing direct ownership by 2% to 421,226 units (SEC Form 4) (for tax liability)
- Chief Commercial Officer Vasanthavada Madhav sold $25,273 worth of shares (4,902 units at $5.16), decreasing direct ownership by 2% to 285,721 units (SEC Form 4) to satisfy withholding tax
- Abeona Therapeutics® Congratulates Ultragenyx on U.S. FDA Approval of FAYUVI™ Gene Therapy for Sanfilippo Syndrome Type A (MPS IIIA)
- Roth Capital initiated coverage on Abeona Therapeutics with a new price target
- Abeona Therapeutics® Announces Activation of University of Florida Health as Newest Qualified Treatment Center for ZEVASKYN®
- Abeona Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Abeona Therapeutics® Announces Participation in Upcoming Investor Conferences
Latest TSHA
- Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Taysha Gene Therapies Announces Multiple Encore Presentations Supporting TSHA-102 Rett Syndrome Clinical Program at the 55th Child Neurology Society Annual Meeting
- Wolfe Research initiated coverage on Taysha Gene Therapies
- Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Amendment: SEC Form SCHEDULE 13G/A filed by Taysha Gene Therapies Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Taysha Gene Therapies Inc.
- SEC Form 10-Q filed by Taysha Gene Therapies Inc.
- Taysha Gene Therapies Inc. filed SEC Form 8-K: Results of Operations and Financial Condition
- Taysha Gene Therapies Reports Second Quarter 2026 Financial Results and Provides Corporate Update
- Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)